Coerente Capital Management Buys 37,096 Shares of Pfizer Inc. $PFE

Coerente Capital Management boosted its stake in Pfizer Inc. (NYSE:PFE) by 5.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 697,710 shares of the biopharmaceutical company’s stock after purchasing an additional 37,096 shares during the quarter. Pfizer comprises about 3.2% of Coerente Capital Management’s holdings, making the stock its 16th biggest position. Coerente Capital Management’s holdings in Pfizer were worth $17,778,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in PFE. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter worth approximately $28,000. Harbor Asset Planning Inc. acquired a new stake in Pfizer in the second quarter valued at approximately $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the second quarter valued at approximately $30,000. Finally, True Wealth Design LLC raised its position in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $25.26 on Thursday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company’s 50 day moving average price is $25.23 and its two-hundred day moving average price is $24.94. The stock has a market cap of $143.61 billion, a P/E ratio of 14.68 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Scotiabank started coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $27.88.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Significant GLP‑1 activity: Pfizer is pursuing GLP‑1 obesity opportunities and recently struck a China licensing deal, which investors view as a potential growth catalyst beyond legacy products. This Could Be Key to Pfizer’s Turnaround in 2026
• Positive Sentiment: Oncology collaboration: Pfizer entered a multi‑year discovery collaboration with Cartography Biosciences to identify tumor‑selective antigens, expanding its immuno‑oncology pipeline potential. Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
• Neutral Sentiment: Vaccine study update: Pfizer provided an update on a Scottish observational study of its RSV maternal vaccine — progress that is worth monitoring but not immediately market moving until clinical readouts or regulatory steps. Pfizer’s Scottish RSV Maternal Vaccine Study: What Investors Should Watch
• Neutral Sentiment: Drug price changes: Reports say Pfizer plans price increases on many medicines starting Jan. 1 — a potential near‑term revenue tailwind but also a regulatory and political risk. Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals
• Neutral Sentiment: Exchange query on Pfizer Limited: A regional exchange sought clarification from Pfizer Limited on past financials — relevant for the local unit but unlikely to materially affect NYSE‑listed PFE unless escalated. Exchange Seeks Clarification from Pfizer Limited on Q2 FY2025 Financial Results
• Negative Sentiment: Litigation risk: A Multi‑District Litigation over Depo‑Provera has set its first trial for December 2026 after an FDA label change; more than 2,100 plaintiffs are involved — an ongoing legal overhang for PFE. Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio
• Negative Sentiment: Analyst caution: UBS initiated a Hold citing patent‑cliff concerns and an uncertain pipeline, limiting upside expectations and pressuring sentiment toward a conservative valuation. Patent Cliff Overhang and Uncertain Pipeline Offset Obesity Upside, Justifying Hold on Fairly Valued Pfizer Shares
• Negative Sentiment: Earnings / guidance pressure: Previews and analysis flag a likely revenue decline and continued margin pressure in 2026, and investors are parsing mixed quarterly results (EPS beat but revenue miss) and FY guidance for signs of sustained growth. Pfizer’s Quarterly Earnings Preview: What You Need to Know

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.